OMass Therapeutics
OMass Therapeutics is developing small molecule drugs to treat diseases and immunological conditions.
OMass Therapeutics has raised €362M across 2 funding rounds from 14 investors, most recently a Series C round in Oct 2026. Based in Oxford, UK; active in Healthtech. Data as of 28 Oct 2026.
Oxford, UKwww.omass.com ↗
Total raised
€362M
€362,068,291
Funding rounds
2
Investors
14
distinct backers
Active since
2022-04
latest 2026-10
Funding by year
EUR raised per year · 2026 YTDOMass Therapeutics — funding by year — interactive chart.
Data table
| OMass Therapeutics — funding by year | |
|---|---|
| 2022 | €90M |
| 2026 | €273M |
Signals
High confidenceRaise-next likelihood19
base rate 50% for Series C
- ▼ Raised very recently
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood22
base rate 11% (2+ rounds)
- ▲ €100M+ raised
- ▲ Recently backed by strong-exit-track investors
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-10-16 | Series C | €273M | Bain Capital Life Sciences,British Business Bank,Forbion,GV,Janus Henderson Investors,Jefferson Life Sciences+7 more | View deal → |
| 2022-04-28 | Series B | €90M | GV,Northpond Ventures,Oxford Science Enterprises,Oxford University Innovation Fund,Sanofi Ventures,Syncona Partners | View deal → |
AI analysis mentioning OMass Therapeutics
1AI-generated analysis · every figure traces to cited rounds.
Investors
14Related news
- Oxford spinout raises £75m to find medicines for rare diseasesbusinesscloud.co.uk · 2022-04
- eu-startups.com
Similar companies
same sector or countryGlobal coverage: FundingData